Phosphorus plays an essential role in the human body, supporting bone health, energy production, and many cellular processes. Under normal conditions, the kidneys maintain phosphate balance by removing excess phosphorus through urine. However, as kidney function declines, this balance becomes increasingly difficult to maintain, allowing phosphate to accumulate in the bloodstream. This condition, known as hyperphosphatemia, has become an important concern in patients with chronic kidney disease (CKD) and kidney failure because of its close relationship with cardiovascular complications, bone disorders, and poorer clinical outcomes.

A recent review published in Nutrients, titled “Hyperphosphatemia in Kidney Failure: Pathophysiology, Challenges, and Critical Role of Phosphorus Management”, discusses the biological mechanisms behind phosphate imbalance and the ongoing challenges of phosphorus control in clinical care.

Figure 1. Hyperphosphatemia in Kidney Failure. Produced by MDPI academic video service (source: https://encyclopedia.pub/video/1810).

1. How Kidney Disease Disrupts Phosphate Balance

In healthy individuals, phosphate levels are regulated through interactions between the kidneys, intestines, bones, and several hormones, including parathyroid hormone (PTH), fibroblast growth factor 23 (FGF-23), and vitamin D. Among these systems, the kidneys play the primary role by filtering and excreting excess phosphate.

As kidney function gradually declines, the body initially attempts to compensate. Levels of FGF-23 and PTH rise in order to increase phosphate excretion and maintain normal serum phosphate levels. Over time, however, these compensatory mechanisms become less effective, leading to phosphate retention and eventually hyperphosphatemia.

The review also highlights the role of αKlotho, a protein involved in FGF-23 signaling. Reduced αKlotho expression in CKD appears to further impair phosphate regulation and may also contribute to cardiovascular complications and disease progression.

2. Why High Phosphate Levels Are a Concern

One of the most significant concerns surrounding hyperphosphatemia is its association with cardiovascular disease, which remains the leading cause of death in patients with kidney failure.

Elevated phosphate levels can contribute to vascular calcification, a process in which calcium-phosphate deposits accumulate within blood vessel walls. This gradually increases arterial stiffness and places additional strain on the cardiovascular system.

Phosphate imbalance is also closely linked to chronic kidney disease–mineral and bone disorder (CKD-MBD). Elevated phosphate and PTH levels disrupt normal bone remodeling, increasing the risk of fractures and other skeletal complications.

In addition, the review notes that elevated FGF-23 levels have been associated with left ventricular hypertrophy, heart failure, and increased mortality risk in CKD patients, further illustrating the broad systemic effects of phosphate dysregulation.

3. The Difficulty of Managing Hyperphosphatemia

Although several treatment strategies are available, phosphorus management remains challenging in clinical practice.

Dialysis can remove phosphate from the bloodstream, but conventional dialysis is often unable to fully control phosphate balance because much of the body’s phosphate is stored in bone and tissues rather than circulating in blood. As a result, phosphate levels can rise again relatively quickly after treatment.

Dietary phosphate restriction is another key strategy, but maintaining adequate nutrition while limiting phosphorus intake is not always straightforward. Many protein-rich foods naturally contain phosphate, and processed foods frequently include phosphate additives that are highly absorbable.

Phosphate binders are commonly prescribed to reduce intestinal phosphate absorption, but these medications can add substantially to pill burden and may affect long-term treatment adherence. The review also discusses newer therapeutic approaches, including intestinal phosphate transport inhibitors such as tenapanor, which may offer additional options for phosphate control.

4. Looking Forward

While phosphorus management is widely considered an important component of CKD care, several questions remain unresolved. The optimal target range for serum phosphate is still debated, and evidence demonstrating that aggressive phosphate lowering directly improves long-term survival remains limited.

Future research will likely focus on improving understanding of phosphate-related hormonal pathways, including FGF-23 and Klotho signaling, while also exploring treatment strategies that better balance phosphate control, nutritional needs, and quality of life.

5. Conclusion

Hyperphosphatemia is more than a simple laboratory abnormality in kidney disease. It reflects a complex disruption of mineral metabolism that is closely associated with cardiovascular disease, bone complications, and increased mortality risk in patients with CKD and kidney failure. As research continues to evolve, a deeper understanding of phosphate biology may help support more individualized and effective treatment strategies for patients living with kidney disease.